Tuettenberg et al. investigated how continuous low doses of the chemotherapeutic drug Temozolomide (TMZ) in combination with the cyclooxygenase-2 (COX-2) inhibitor, Rofecoxib, affected angiogenesis in glioblastomas (GBMs), which suggests a possible novel antiangiogenic strategy for treatment [16]. The gene discussed is PTGS2; the disease is glioblastoma.